A Novel Oral Drug for the Treatment of Moderate to Severe Crohn's Disease Would Earn 40 Percent Patient Share in the U.S. and Europe
Advertisement
Abbott/Eisai's Humira Will Remain Decision Resources' Proprietary Clinical Gold Standard Through 2018, According to a New Report from Decision Resources
